Parallel-Group,Double-Blind,Double-Dummy,Superiority Study of Etoricoxib90mg/ Cyclobenzaprine15mg From Eurofarma Versus Etoricoxib90mg (Arcoxia®) and Cyclobenzaprine15mg (XL - Mitrul®) for Muscle Spasm After Third Molar Extraction in Brazil

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclobenzaprine/etoricoxib (Primary) ; Cyclobenzaprine; Etoricoxib
Indications Postoperative pain
Focus Registrational; Therapeutic Use
Acronyms BENCOX
Sponsors Eurofarma

Most Recent Events

26 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Change in study strategy.)
26 Jan 2024 Planned End Date changed from 30 Jun 2026 to 28 Feb 2028.
26 Jan 2024 Planned primary completion date changed from 30 Nov 2025 to 30 Oct 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight